Finally, our findings suggest that testing for AQP4 antibodies not only enables a reliable distinction to be made between NMO and MS, but also facilitates differential diagnosis concerning other autoimmune diseases affecting the CNS. Here, AQP4 is linked to myeloid sarcoma.